Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3184774 | 0.82 | MEN1 (0.37) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL10936788 | 0.80 | RXRA (0.47) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3174611 | 0.80 | TUBB1 (0.44) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL10936348 | 0.78 | GAA (0.46) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1817008 | 0.72 | ALDH1A1 (0.58) | MEN1KMT2ATUBB1RAB9AABCG2 | |
| SCHEMBL3220583 | 0.72 | GAA (0.53) | CYP1A2RAB9ANPC1KDM4EGAA | |
| SCHEMBL3177999 | 0.70 | CYP1A2 (0.58) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7063684 | 0.70 | FLT3 (0.75) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL708815 | 0.69 | FLT3 (0.60) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| 3,5-Dimethoxybenzoic Acid SCHEMBL5668197 | 0.68 | RXRA (0.62) | RAB9ANPC1ABCG2KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718087-B2 | Organic iridium compositions and their use in electronic devices | GENERAL ELECTRIC COMPANY (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718277-B2 | Electronic devices comprising organic iridium compositions | GENERAL ELECTRIC COMPANY (US) | 2010-05-18 | — | — | US | disclosed |
| US-7704610-B2 | organic light emitting device comprising deuterated organic iridium complex; optoelectronic devices, photovoltaic devices; enhanced color properties and light output efficiencies | GENERAL ELECTRIC COMPANY (US) | 2010-04-27 | — | — | US | disclosed |
| US-20100090586-A1 | ELECTRONIC DEVICES COMPRISING ORGANIC IRIDIUM COMPOSITIONS | GENERAL ELECTRIC COMPANY | 2010-04-15 | — | — | US | disclosed |
| US-7695640-B2 | Organic iridium compositions and their use in electronic devices | GENERAL ELECTRIC COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-7691292-B2 | organic light emitters; photovoltaic cells; electrophosphorescent | GENERAL ELECTRIC COMPANY (US) | 2010-04-06 | — | — | US | disclosed |
| US-7691494-B2 | Electronic devices comprising organic iridium compositions | GENERAL ELECTRIC COMPANY (US) | 2010-04-06 | — | — | US | disclosed |
| US-20100051869-A1 | ORGANIC IRIDIUM COMPOSITIONS AND THEIR USE IN ELECTRONIC DEVICES | GENERAL ELECTRIC COMPANY | 2010-03-04 | — | — | US | disclosed |
| US-7652151-B2 | Ketopyrroles useful as ligands in organic iridium compositions | GENERAL ELECTRIC COMPANY (US) | 2010-01-26 | — | — | US | disclosed |
| US-7608677-B2 | Method for preparing polymeric organic iridium compositions | GENERAL ELECTRIC COMPANY (US) | 2009-10-27 | — | — | US | disclosed |
| EP-2049555-A2 | ORGANIC IRIDIUM COMPOSITIONS AND THEIR USE IN ELECTRONIC DEVICES | GENERAL ELECTRIC COMPANY (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20080023672-A1 | Organic iridium compositions and their use in electronic devices | GENERAL ELECTRIC COMPANY | 2008-01-31 | — | — | US | disclosed |
| US-20080026249-A1 | Electronic devices comprising organic iridium compositions | GENERAL ELECTRIC COMPANY | 2008-01-31 | — | — | US | disclosed |
| US-20080023671-A1 | Organic iridium compositions and their use in electronic devices | GENERAL ELECTRIC COMPANY | 2008-01-31 | — | — | US | disclosed |
| US-20080026250-A1 | Electronic devices comprising organic iridium compositions | GENERAL ELECTRIC COMPANY | 2008-01-31 | — | — | US | disclosed |
| US-20080027028-A1 | Ketopyrroles useful as ligands in organic iridium compositions | GENERAL ELECTRIC COMPANY | 2008-01-31 | — | — | US | disclosed |
| WO-2008014037-A2 | ORGANIC IRIDIUM COMPOSITIONS AND THEIR USE IN ELECTRONIC DEVICES | GENERAL ELECTRIC COMPANY (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20080026477-A1 | Method for preparing polymeric organic iridium compositions | GENERAL ELECTRIC COMPANY (US) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027028-A1 | Ketopyrroles useful as ligands in organic iridium compositions | OR10J3, OPRD1, OCIAD1 | MEN1 4691/4885KMT2A 2512/4885CYP1A2 780/4885 |
| US-20100051869-A1 | ORGANIC IRIDIUM COMPOSITIONS AND THEIR USE IN ELECTRONIC DEVICES | OCIAD1, OCIAD2, OXER1 | MEN1 3896/4885KMT2A 3401/4885CYP1A2 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.